Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.
Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.
Avalo Therapeutics (Nasdaq: AVTX) reported Q1 2026 results and key business updates.
The company announced positive topline Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa, completed a $431.3 million equity offering, and ended March 31, 2026 with $82 million in cash and investments, excluding the subsequent financing, which is expected to fund operations into 2029.
Q1 2026 net loss was $19.6 million on higher R&D and G&A expenses.
Avalo Therapeutics (NASDAQ: AVTX) priced an underwritten public offering to raise approximately $375 million in gross proceeds by selling 19,730,000 shares of common stock and pre-funded warrants to purchase 1,400,000 shares.
The offering price is $17.75 per share and $17.749 per pre-funded warrant; the underwriters have a 30-day option for up to 3,169,500 additional shares. Closing is expected May 7, 2026, subject to customary conditions. Net proceeds will fund Phase 3 development of abdakibart and general corporate purposes.
Avalo Therapeutics (NASDAQ: AVTX) commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants on May 5, 2026. Avalo may grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered.
Proceeds, together with existing cash and investments, are intended to fund clinical development of abdakibart including Phase 3 topline data release, and for working capital and general corporate purposes. Leerink Partners, TD Cowen and BofA Securities are joint bookrunners. The securities are offered under Avalo’s effective Form S-3 shelf registration (No. 333-292614).
Avalo Therapeutics (NASDAQ: AVTX) reported positive topline Phase 2 LOTUS results for abdakibart (AVTX-009) in moderate to severe hidradenitis suppurativa on May 5, 2026. The trial met its primary endpoint HiSCR75 at Week 16 for both doses (42.2% at 150 mg, 42.9% at 300 mg; placebo 25.6%), showed significant secondary endpoint benefits, enrolled 253 adults, and observed a favorable safety profile. Avalo plans a registrational Phase 3 program and will present full results at a medical congress.
Avalo Therapeutics (Nasdaq: AVTX) entered a Milestone Buyout Option and Amendment Agreement related to its March 2024 acquisition of AlmataBio. Avalo paid $2.25 million for an option, exercisable within 90 days, to pay an additional $5.125 million in cash, stock, or combination.
If exercised, that payment replaces a previously disclosed $15 million contingent milestone tied to first patient dosing in a Phase 3 trial.
Avalo Therapeutics (Nasdaq: AVTX) reported 2025 results and operational updates, highlighting upcoming Phase 2 LOTUS topline data for abdakibart (AVTX-009) expected in Q2 2026. Cash, cash equivalents and short-term investments were $98.3 million as of December 31, 2025, which the company expects will fund operations into 2028.
2025 R&D expenses rose to $50.1M; net loss was $78.3M for 2025 versus $35.1M in 2024, driven by higher R&D and nonrecurring 2024 items.
Avalo Therapeutics (Nasdaq: AVTX) will present at two investor conferences in March 2026: a TD Cowen Annual Healthcare Conference fireside chat on March 3, 2026 at 9:50 am ET and a Leerink Partners Global Healthcare Conference fireside chat on March 10, 2026 at 4:20 pm ET.
Live webcasts and archived replays will be available via the company's Investors "News / Events" page, with archived access for at least 30 days.
Avalo Therapeutics (Nasdaq: AVTX) granted inducement equity awards to two new employees under Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee approved nonstatutory stock options on Feb. 13, 2026 to purchase an aggregate of 82,000 shares at an exercise price of $14.26 per share, equal to the closing price on the grant date. Options vest 25% after one year, then monthly over 36 months, subject to continued service and the 2025 Inducement Award Plan terms.
Avalo Therapeutics (Nasdaq: AVTX) said its management will present at two investor conferences in February 2026: a Guggenheim Emerging Outlook Biotech Summit fireside chat on February 11, 2026 at 10:00 AM ET and an Oppenheimer Healthcare Life Sciences fireside chat on February 25, 2026 at 10:00 AM ET.
Live webcasts and replays will be posted under News / Events on the Avalo Therapeutics investor website, with archived webcasts available for at least 30 days.
Avalo Therapeutics (Nasdaq: AVTX) announced inducement equity awards under Nasdaq Listing Rule 5635(c)(4) for three newly hired employees totaling 114,000 nonstatutory stock options.
The Options were granted on Nov 4, Nov 10, and Nov 17, 2025 and break down as 24,000, 72,000, and 18,000 shares respectively. Exercise prices are set equal to the closing price on each grant date. Vesting is over 4 years with 25% vesting at the one-year anniversary and the remainder vesting monthly over 36 months, subject to continued service. Awards are governed by Avalo’s 2025 Inducement Award Plan and individual option agreements.